KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Influence of anti-Spike protein antibody levels on tocilizumab efficacy in hospitalized patients with severe COVID-19 pneumonia: a post-hoc analysis of the COVACTA trial.

José Aguareles, Carles Forné, Ana García-Casas, Guillermo Santamaría-Corral, Daniel Carnevali-Ruiz, Gabriel Sotres-Fernández, Javier T Solera, Pablo Guisado-Vasco

BMC Infect Dis 25(1) 676

PMID40340657
PMCIDPMC12063319
DOI10.1186/s12879-025-11001-6
发表日期2025-05-09
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 multi panel km;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other。
摘要

摘要

BACKGROUND: Our aim in this work is to find biomarkers to optimize therapy with IL-6 inhibitors, as not all clinical trials have shown clear benefits on mortality or mechanical ventilation progression. Given the link between delayed seroconversion and higher complication risks, we aim to test if evaluating SARS-CoV-2 spike protein antibody status before treatment could enhance IL-6 inhibitor therapy effectiveness in COVID-19 patients. METHODS: We conducted a post hoc analysis of the COVACTA study, a phase 3, randomized, double-blind, placebo-controlled trial of the efficacy and safety of tocilizumab in hospitalized patients with severe COVID-19. Cox and logistic regression analysis were used to assess the tocilizumab's efficacy in severe COVID-19 patients on survival and ICU stay at day 28, based on SARS-CoV-2 S-spike and neutralizing antibody levels. RESULTS: Tocilizumab reduced 28-day mortality over placebo in patients with low S-spike antibody titers (20% vs. 29%). No benefit was observed for higher antibody levels. Patients with low S-spike antibody levels treated with tocilizumab exhibited a lower probability of ICU stay at day 28 compared to those treated with placebo (63% vs. 82%). No significant differences were noted in mortality and ICU stay based on whole neutralizing antibody titers. CONCLUSIONS: Our findings suggest that using IL-6 inhibitors in severe COVID-19 patients with low S-spike antibody titers may improve clinical outcomes. CLINICAL TRIAL: Not applicable.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Outcomes of the population from COVACTA trial based on treatment and S-spike Ab levels Probability of mortality at day 28 and 95% CI by (a) study arm and S-spike Ab levels adjusted for sex, age, days from symptoms, and baseline ICU stay, or by (b) study arm and spike protein dichotomized (median = 57.66 U/mL) adjusted for sex, age, days from symptoms, and baseline ICU stay. Mean was 0.20 (0.08 to 0.31) in the tocilizumab group with low levels of S-spike Ab patients and 0.29 (0.10 to 0.45) in the placebo group with low levels of S-spike Ab (LRT p-value = 0.049). Probability of ICU stay at day 28 and 95% CI by (c) study arm and S-spike Ab levels adjusted for sex, age, and days from symptoms, or by (d) study arm and spike protein dichotomized (median = 57.66 U/mL) adjusted for sex, age, and days from symptoms. Mean was 0.63 (0.50 to 0.74) in the tocilizumab group with low levels of S-spike Ab patients and 0.82 (0.68 to 0.91) in the placebo group with low levels of S-spike Ab (LRT p-value = 0.022). PBO = placebo, TCZ = tocilizumab
非 KM Figure
Fig. 2Fig. 2 Outcomes of the population from the COVACTA trial based on treatment and neutralizing Ab titers Probability of mortality at day 28 and 95% CI by (a) study arm and neutralizing Ab titers adjusted for sex, age, days from symptoms, and baseline ICU stay, or by (b) study arm and neutralizing Ab titers dichotomized (median = 83) adjusted for sex, age, days from symptoms, and baseline ICU stay. Mean was 0.22 (0.11 to 0.31) in the tocilizumab group with low titers of neutralizing Ab and 0.21 (0.08 to 0.33) in the placebo group with low levels of neutralizing Ab (LRT p-value = 0.427). Probability of ICU stay at day 28 and 95% CI by (c) study arm and neutralizing Ab titers adjusted for sex, age, and days from symptoms or by (d) study arm and neutralizing Ab titers dichotomized (median = 83) adjusted for sex, age, and days from symptoms. Mean was 0.60 (0.49 to 0.71) in the tocilizumab group with low levels of neutralizing Ab titers and 0.79 (0.65 to 0.89) in the placebo group with low levels of neutralizing Ab titers (LRT p-value = 0.111). PBO = placebo, TCZ = tocilizumab
非 KM Figure
Fig. 3Fig. 3 7-Category ordinal scale at day 28, according to the category at baseline, stratified by S-spike Ab. Percentage of patients in each category of the ordinal scale at day 28 in each arm of treatment and grade at baseline in patients with (a) low levels of SARS-CoV-2 Spike Protein Abs (levels below 57.66 U/mL) and (b) high levels of SARS-CoV-2 Spike Protein Abs (levels above 57.66 U/mL). Below each bar plot, the contingency table of each graph is represented. The 7 categories are as follows: (1) discharged/ready for discharge, (2) non-ICU hospital ward/ready for hospital ward, not requiring supplemental oxygen, (3) non-ICU hospital ward/ready for hospital ward, requiring supplemental oxygen, (4) ICU or non-ICU hospital ward, requiring noninvasive ventilation or high-flow oxygen, (5) ICU, requiring intubation and mechanical ventilation, (6) ICU, requiring extracorporeal membrane oxygenation or mechanical ventilation and additional organ support, (7) death. PBO = placebo, TCZ = tocilizumab
非 KM Figure